INDEMNIFICATION AGREEMENTIndemnification Agreement • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations • Delaware
ESCROW SERVICES AND CUSTODY AGREEMENTEscrow Services and Custody Agreement • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations • Virginia
This Escrow Services and Custody Agreement (this “Agreement”) is effective this 8th day of November, 2016 (the “Effective Date”) by and among Stocosil, Inc., a Delaware corporation (“Issuer”), and Folio Investments, Inc. (“Folio”), a Virginia corporation. Issuer and Folio are hereby referred to collectively as the “Parties” or individually as a “Party”.
CONSULTING & COORDINATION RETAINER AGREEMENT:Consulting & Coordination Retainer Agreement • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations • California
Stocosil Inc., a Delaware corporation with an address of 17870 Castleton St., Ste. 250, City of Industry, CA 91765 (“Company”), is intending to engage in a public offering of securities pursuant to an exemption from registration pursuant to Section 3(b) of the Securities Act of 1933, as amended (the “Act”) and Regulation A+ promulgated thereunder (the “Offering”). Both parties may be hereinafter referred to each individually as a “Party” and collectively as the “Parties”. This Agreement supersedes and replaces any and all prior agreements between the parties.
SECOND AMENDED AND RESTATED ENGAGEMENT LETTEREngagement Letter • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations • Delaware
This second amended and restated engagement letter (the “Agreement”) confirms the terms upon which Stocosil Inc. (the “Client”) engages Boustead Securities, LLC (f/k/a Monarch Bay Securities, LLC) (“Boustead” or the “Placement Agent”). The Placement Agent is engaged to act as the exclusive placement agent to the Client in connection with a Financing (as defined below) of securities on behalf of the Client. The Placement Agent is also the “Financial Adviser,” which the Client hereby engages upon signing this Agreement. This Agreement amends, restates and supersedes in its entirety that certain Amended and Restated Engagement Letter dated September 19, 2016 between the Client and the Placement Agent (the “Original Letter”).
PRODUCT DEVELOPMENT, LICENCE AND COMMERCIALIZATION AGREEMENTProduct Development, Licence and Commercialization Agreement • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations
This Product Development, Licence and Commercialization Agreement (“Agreement”) is made and entered into as of February 27th, 2015 by and between Daewoong Pharmaceuticals Co. Ltd. a company incorporated under the laws of South Korea and having its registered office at 163-3, Samsung-Dong, Kangnam-Gu, Seoul, Korea (“DAEWOONG”) and Autotelic, LLC and Autotelic, Inc., and Stocosil Inc. (“STOCOSIL”) companies incorporated under the laws of Delaware, having its registered office at 17870 Castleton Street, Ste. 250, City of Industry, CA 91748, USA. (“STOCOSIL”).
